Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

bioAffinity Technologies (BIAF) Share-based Compensation (2022 - 2025)

bioAffinity Technologies (BIAF) has disclosed Share-based Compensation for 4 consecutive years, with $67132.0 as the latest value for Q3 2025.

  • On a quarterly basis, Share-based Compensation fell 63.85% to $67132.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $839442.0, a 15.22% decrease, with the full-year FY2024 number at $989681.0, up 32.16% from a year prior.
  • Share-based Compensation was $67132.0 for Q3 2025 at bioAffinity Technologies, down from $211607.0 in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $326616.0 in Q1 2025 to a low of $26685.0 in Q2 2022.
  • A 4-year average of $166083.4 and a median of $170255.0 in 2023 define the central range for Share-based Compensation.
  • Peak YoY movement for Share-based Compensation: soared 538.02% in 2023, then tumbled 63.85% in 2025.
  • bioAffinity Technologies' Share-based Compensation stood at $36847.0 in 2022, then soared by 536.44% to $234510.0 in 2023, then fell by 0.18% to $234087.0 in 2024, then tumbled by 71.32% to $67132.0 in 2025.
  • Per Business Quant, the three most recent readings for BIAF's Share-based Compensation are $67132.0 (Q3 2025), $211607.0 (Q2 2025), and $326616.0 (Q1 2025).